What does this research mean for the field?

Mirikizumab provides sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in patients with moderately-to-severely active ulcerative colitis. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the long-term efficacy and safety of mirikizumab in patients with moderately-to-severely active ulcerative colitis.

March 6, 2026

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Key Points

To evaluate the long-term efficacy and safety of mirikizumab in patients with moderately-to-severely active ulcerative colitis.
Conducted an open-label extension study over four years
Included patients with prior biologic failure
Assessed symptomatic, clinical, endoscopic, and histologic outcomes
Mirikizumab provided sustained symptomatic benefits over four years
Patients experienced significant improvements in clinical and endoscopic measures
Histologic benefits were also observed in responding patients

Abstract

Mirikizumab provided sustained symptomatic, clinical, endoscopic, and histologic benefits over 4 years in responding patients with moderately-to-severely active UC, including those with prior biologic failure. These treatment goals, which are integral to comprehensive disease management, support the long-term use of mirikizumab.

Bookmark

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

Key Points

Abstract

Cite This Study